上海交通大学学报(医学版)

• 论著(基础研究) • 上一篇    下一篇

CIP2A和CK2β蛋白在食管鳞状细胞癌中的表达及其与预后的关系

李红伟1,李多杰1,柴大敏2,江浩1,汪朝歌1,马莉2   

  1. 蚌埠医学院第一附属医院 1.放疗科, 2.病理科, 蚌埠 233003
  • 出版日期:2016-02-28 发布日期:2016-03-29
  • 通讯作者: 马莉, 电子信箱: mali-790410@163.com。
  • 作者简介:李红伟(1981—), 男, 主治医师, 讲师, 硕士; 电子信箱: l80h02w20@163.com。
  • 基金资助:

    蚌埠医学院基金(Byky1239);高等学校省级优秀青年人才基金(2011SQR081); 安徽省卫生厅“十二五”临床重点专科建设基金(01Z33)

Expressions of CIP2A and CK2β in tissues of esophageal squamous cell carcinoma and the correlation with prognosis

LI Hong-wei1, LI Duo-jie1, CHAI Da-min2, JIANG Hao1, WANG Chao-ge2, MA Li1   

  1. 1.Department of Radiotherapy, 2.Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233003, China
  • Online:2016-02-28 Published:2016-03-29
  • Supported by:

    Foundation of Bengbu Medical College, Byky1239; Excellent Young Talents Foundation in Colleges of Anhui, 2011SQR081; Clinical Key Specialty Construction Foundation of Anhui Provincial Health Office in the “12th Five-year Plan”, 01Z33

摘要:

目的 探讨CIP2A和CK2β蛋白在食管鳞状细胞癌(ESCC)组织中的表达意义及对患者预后的影响。方法 采用免疫组织化学法检测155例ESCC 组织(实验组)、50例癌旁正常黏膜组织(对照组)中CIP2A和CK2β蛋白的表达,分析CIP2A和CK2β蛋白表达水平及与临床病理参数之间的关系,应用Kaplan-Meier生存分析和Cox多因素分析对ESCC患者的生存情况进行分析。结果 CIP2A和CK2β蛋白在ESCC组织中的表达阳性率分别为76.67%和66.45%,均明显高于正常对照组的16.00%和12.00%,差异有统计学意义(均P=0.000)。CIP2A蛋白与ESCC的淋巴结转移及临床分期有关(P=0.005,P=0.000),而与患者的年龄、性别、组织学分级和浸润深度等无相关性。CK2β蛋白的表达与ESCC的组织学分级、淋巴结转移和临床分期有关(P=0.000,P=0.004,P=0.000),而与患者的年龄、性别和浸润深度无相关性。CIP2A与CK2β蛋白表达呈正相关(r=0.611,P=0.000)。ESCC患者总体5年生存率为23.33%。CIP2A蛋白表达阳性患者的5年生存率为8.11%(9/111),阴性者为66.67%(26/39),差异具有统计学意义(P=0.000)。CK2β蛋白表达阳性患者的5年生存率为6.06%(6/99),阴性者为56.86%(29/51),差异具有统计学意义(P=0.000)。Cox多因素预后分析显示,TNM临床分期和CIP2A及CK2β蛋白表达水平是影响ESCC患者预后的独立因素(P=0.008,P=0.013,P=0.000)。结论 CIP2A和CK2β的表达与ESCC发生及发展密切相关,其可能参与了ESCC的浸润及转移,阳性表达者预后较差。联合检测2种蛋白的表达对判断ESCC的预后具有重要意义。

关键词: 食管鳞状细胞癌;CIP2A;CK2&beta, ;预后

Abstract:

Objective To investigate the significance of expressions of phosphatase 2A (CIP2A) and kinase 2 beta (CK2β) in tissues of esophageal squamous cell carcinoma (ESCC) and the effect on the prognosis of patients. Methods Immunohistochemical staining was used to detect the expressions of CIP2A and CK2β in 155 tissue samples of ESCC (experiment group) and 50 adjacent normal mucous membrane tissues (control group). The correlation between the expressions of CIP2A and CK2β and the clinical pathological parameters was analyzed. Kaplan-Meier survival analysis and Cox multivariate analysis were adopted to analyze the survival of patients with ESCC. Results The positive rates of expressions of CIP2A and CK2β in tissues of ESCC were 76.67% and 66.45%, which were remarkably higher than 16.00% and 12.00% of the control group. The differences were statistically significant (P=0.000). CIP2A was correlated with lymph node metastasis and TNM stage of patients with ESCC (P=0.005, P=0.000), while was not correlated with age, gender, histological grade, and depth of invasion. The expression of CK2β was correlated with histological grade, lymph node metastasis, and TNM stage of patients with ESCC (P=0.000,P=0.004,P=0.000), while was not correlated with age, gender, and depth of invasion. The expression of CIP2A was positively correlated with the expression of CK2β (r=0.611,P=0.000). The overall 5-year survival rate of patients with ESCC was 23.33%. The 5-year survival rate of patients with positive expression of CIP2A was 8.11% (9/111) and that of patients with negative expression of CIP2A was 66.67% (26/39). The differences were statistically significant (P=0.000). The 5-year survival rate of patients with positive expression of CK2β was 6.06% (6/99) and that of patients with negative expression of CK2β was 56.86% (29/51). The differences were statistically significant (P=0.000). Cox multivariate analysis revealed that the TNM stage and expression levels of CIP2A and CK2β were independent risk factors of influencing the prognosis of patients with ESCC (P=0.008,P=0.013, P=0.000). Conclusion Expressions of CIP2A and CK2β are closely related with the occurrence and development of ESCC and may involve in the invasion and metastasis of ESCC. The prognosis of patients with positive expressions is poor. Combined detection of expressions of CIP2A and CK2β is vital for predicting the prognosis of patients with ESCC.

Key words: esophageal squamous cell carcinoma, CIP2A, CK2β, prognosis